Lenalidomide, sold under the trade name Revlimid among others, is a medication used to treat multiple myeloma (MM) and myelodysplastic syndromes (MDS).[1] For MM it is used after at least one other treatment and generally together with dexamethasone.[1] It is taken by mouth.[1] Common side effects include diarrhea
Pregnancy category: AU: X (High risk), US:
Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company’s major product is Revlimid (lenalidomide), in combination with dexamethasone for the
Headquarters: Summit, New Jersey, U.S.
Lenalidomid (Handelsname: Revlimid, Hersteller: Celgene) ist ein Arzneistoff aus der Gruppe der Immunmodulatoren. Es ist strukturell mit dem Thalidomid und Pomalidomid verwandt und wird wie diese zur Behandlung des Multiplen Myeloms, der und des
EG-Nummer: 691-297-1
La lenalidomida es un medicamento derivado de la talidomida aparecido en el año 2004 y empleado en el tratamiento del mieloma múltiple[1] y la leucemia linfática crónica.[2] [3]
Fórmula: C₁₃H₁₃N₃O₃
Multiple myeloma (MM), also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood cell which normally produces antibodies. Often, no symptoms are noticed initially. As it progresses, bone pain, bleeding, frequent infections, and anemia may occur.
Complications: Amyloidosis, kidney problems, bone
Le lénalidomide (REVLIMID) est une molécule utilisée comme médicament, dérivée du thalidomide et apparue en 2004. Mode d’action Le lénalidomide est un médicament capable de modifier ou de réguler le fonctionnement du système immunitaire. il détruit
Formule brute: C₁₃H₁₃N₃O₃ [Isomères]
Thalidomide, sold under the brand name Thalomid,[3] among others, is an immunomodulatory drug and the prototype of the thalidomide class of drugs. It is mainly used as a treatment of certain cancers (multiple myeloma) and of a complication of leprosy. It is on the World Health Organization’s List of Essential Medicines, the
Pregnancy category: AU: X (High risk), US:
レナリドミドまたはレナリドマイド（英名: Lenalidomide）とは免疫調節薬 (IMiDs)。2005年に登場した。 洛德城堡親子水上樂園 【臺北旅遊】洛德城堡水上 商品名レブラミド（セルジーン株式会社）。 鼎湖山門票 鼎湖山 2013年現在、再発もしくは難治性の多発性骨髄腫（Multiple Myeloma: MM）[1]と5番染色体長腕部欠失を伴う骨髄異形
法的規制: US: ℞-only
Lenalidomide (tên thương mại Revlimid) là một dẫn xuất của thalidomide được phê duyệt tại Hoa Kỳ vào năm 2005.[1] Ban đầu nó được dự định là một phương pháp điều trị đa u tủy, trong đó thalidomide là một phương pháp điều trị được chấp nhận. Lenalidomide cũng
Danh mục cho thai kỳ: AU: X (Nguy cơ cao), US: X
Celgene ist ein amerikanisches Pharmaunternehmen, das sich auf die Herstellung von Arzneimitteln gegen Krebserkrankungen und Krankheiten des Immunsystems spezialisiert hat. Der Sitz von Celgene befindet sich in Summit, New Jersey. Das sich als biopharmaceutical company beschreibende Unternehmen beschäftigt rund 7.500 Mitarbeiter bei
Leitung: Mark J. Alles, CEO
Lenalidomide (tên thương mại Revlimid) là một dẫn xuất của thalidomide được phê duyệt tại Hoa Kỳ vào năm 2005.[1] Ban đầu nó được dự định là một phương pháp điều trị đa u tủy, trong đó thalidomide là một phương pháp điều trị được chấp nhận. Lenalidomide cũng
Sử dụng trong y tế ·
レナリドミドまたはレナリドマイド（英名: Lenalidomide）とは免疫調節薬 (IMiDs)。2005年に登場した。 金盞花植物精華爽膚水暗瘡 商品名レブラミド（セルジーン株式会社）。 貴婦膏女人我最大 2013年現在、再発もしくは難治性の多発性骨髄腫（Multiple Myeloma: MM）[1]と5番染色体長腕部欠失を伴う骨髄異形
多発性骨髄腫 ·
Celgene ist ein amerikanisches Pharmaunternehmen, das sich auf die Herstellung von Arzneimitteln gegen Krebserkrankungen und Krankheiten des Immunsystems spezialisiert hat. Der Sitz von Celgene befindet sich in Summit, New Jersey. Das sich als biopharmaceutical company beschreibende Unternehmen beschäftigt rund 7.500 Mitarbeiter bei
Geschichte ·
La lenalidomide, nota inizialmente come “CC-5013”, è un farmaco derivato dal talidomide, impiegato per il trattamento del mieloma multiplo e delle sindromi mielodisplasiche. Si tratta di un agente immunomodulante, cioè che interferisce sull’attività del sistema immunitario. Essa blocca lo sviluppo delle cellule tumorali, inibisce l
Utilizzo nel mieloma multiplo ·
Use of Lenalidomide (Revlimid) requires participation the Revlimid REMS program. [4] For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.
Het is op recept verkrijgbaar onder de merknaam Revlimid in capsules. Dit medicijn kan ernstige bijwerkingen bij de ongeboren baby geven. Het voorschrijven, afleveren en gebruik van lenalidomide kan alleen als aan strenge regels van de overheid met betrekking
About REVLIMID® (lenalidomide) treatment for deletion 5q myelodysplastic syndromes, mantle cell lymphoma and multiple myeloma including full indications, dosing, administration, efficacy, safety & prescribing information.
Lenalidomid Klinički podaci Prodajno ime Ladevina, Lenangio, Revlimid Drugs.com Način primene Oralno Farmakokinetički podaci Poluvreme eliminacije 3 h Izlučivanje Renalno Identifikatori CAS broj 191732-72-6 ATC kod L04AX04 PubChem CID 216326 DrugBank
Osobine ·
Lenalidomid Klinički podaci Robne marke Ladevina, Lenangio, Revlimid AHFS/Drugs.com Identifikatori CAS broj ATC kod L04 PubChem DrugBank ChemSpider ChEBI ChEMBL Hemijski podaci Formula C 13 H 13 N 3 O 3 Mol. masa 259,261 SMILES
Osobine ·
歷史 它本是塞拉尼斯公司旗下一部門， 風再起時小鴨 1986年獨立出來自成門戶。 ui框架 bui框架官網 專注webapp快速開發 2015年7月1日斥資8.5億美元購入朱諾醫療10%的股權。 2015年7月16日以72億美金收購Receptos。 池化和卷積的區別 2018年1月28日預先支付11億美元收購Impact Biomedicines， 電腦配件 以取得仍在實驗中的血癌治療藥物。 世界明珠開發案
歷史 ·
Lenalidomida (nome comercial Revlimid ) é um fármaco utilizado no tratamento de mieloma múltiplo e da síndrome mielodisplásica. É uma droga imunomoduladora, derivada da talidomida, introduzido no mercado em 2004. Esse medicamento oral é indicado, em combinação com a dexametasona, para o tratamento de pacientes com mieloma
8/4/2018 · Revlimid could face competition from vastly cheaper “copycat” versions from 2020 if generic drugmakers are successful in their legal efforts to overturn its patents, which would result in dramatically lower sales of the medicine.
Instruct patient to take lenalidomide as directed and to comply with all aspects of the Revlimid REMSprogram. Take missed doses as soon as remembered within 12 hr of dose missed. If more than 12 hrs, skip dose and return to next scheduled dose; do not
Learn about multiple myeloma Select the blue, bold terms for more information. Multiple myeloma is a blood cancer that affects the plasma cells in your blood. Take a few moments to learn more about multiple myeloma and why treatment is important. Select a path
Learn how Celgene, a global biopharmaceutical company, is committed to improving the lives of patients worldwide by delivering truly innovative and life-changing treatments. Explore the therapies for Hematology, Oncology, Inflammation and Immunology and the
Celgene Corporation Tüüp börsiettevõte (NASDAQ: CELG) Asutatud 1986 Asutajad Sol J. Barer Peakorter Summit, New Jersey, USA Võtmeisikud Robert J. Hugin (juhatuse esimees) Mark Alles Valdkonnad biotehnoloogia Tooted Revlimid, Abraxane, Pomalyst
Celgene è una società biofarmaceutica americana, con sede centrale a Summit, nel New Jersey, e attività in diversi paesi. È completamente integrata: scopre, sviluppa e commercializza farmaci per il cancro e i disturbi infiammatori. Il prodotto principale dell’azienda è Revlimid (lenalidomide), in associazione con desametasone per
Storia ·
Immunomodulatory drugs (IMiDs) CC-5013 (Revlimid TM, Lenalidomide) and CC-4047 (ActimidTM, Pomalidomide) are a series of synthetic compounds derived using structural modifications of the chemical structure of thalidomide.
2005年12月， Celgene的新药Revlimid获得FDA批准上市， 店到店多久到 途虎 用于治疗治疗输血依赖性贫血；2006年5月， 四海大廈英文 四海大廈 Celgene公司获准用Thalamid结合地塞米松对多发性骨髓瘤初诊患者进行治疗；2008年3月， 蝦皮克客服 皮克直播 以2.9亿美金收购Pharmion Corporation；2009年12月， 如何克服選擇恐懼作文 Celgene收购
Daratumumab is een experimentele monoklonale antistof die wordt ingezet tegen multipel myeloom. Daratumumab bindt aan CD38.[1] Daratumumab werd oorspronkelijk ontwikkeld door Genmab, maar wordt nu doorontwikkeld in samenwerking met Janssen Biotech, een dochteronderneming van Johnson & Johnson. De wereldwijde rechten op het medicament
Celgene Corporation Tüüp börsiettevõte (NASDAQ: CELG) Asutatud 1986 Asutajad Sol J. Barer Peakorter Summit, New Jersey, USA Võtmeisikud Robert J. Hugin (juhatuse esimees) Mark Alles Valdkonnad biotehnoloogia Tooted Revlimid, Abraxane, Pomalyst
Celgene è una società biofarmaceutica americana, con sede centrale a Summit, nel New Jersey, e attività in diversi paesi. È completamente integrata: scopre, sviluppa e commercializza farmaci per il cancro e i disturbi infiammatori. Il prodotto principale dell’azienda è Revlimid (lenalidomide), in associazione con desametasone per
Storia ·
Immunomodulatory drugs (IMiDs) CC-5013 (Revlimid TM, Lenalidomide) and CC-4047 (ActimidTM, Pomalidomide) are a series of synthetic compounds derived using structural modifications of the chemical structure of thalidomide.
· PDF 檔案
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use REVLIMID® safely and effectively. See full prescribing information for REVLIMID. REVLIMID [lenalidomide] capsules, for oral use Initial U.S
Celgene Corporation on yhdysvaltalainen lääketeollisuusyritys, joka kehittää, tuottaa ja markkinoi lääkkeitä syövän sekä muiden vaikeiden immuuni- ja tulehdussairauksien hoitoon.[2] Se on pörssiyhtiö, jonka osake kuuluu Nasdaq-100- ja S&P 500 -indekseihin. Celgenen
Questa pagina è stata modificata per l’ultima volta il 2 gen 2019 alle 10:14. I file sono disponibili secondo la licenza indicata nella loro pagina di descrizione. Tutti i dati strutturati del file e del namespace proprietà sono disponibili con licenza Creative Commons CC0; tutto il testo strutturato è disponibile con
Thalidomid (α-Phthalimidoglutarimid) ist ein Arzneistoff, der als Schlaf-und Beruhigungsmittel unter den Markennamen Contergan und Softenon verkauft wurde und Ende der 1950er/Anfang der 1960er-Jahre zu zahlreichen schweren Schädigungen an ungeborenem
Geschichte ·
Lenalidomide | C13H13N3O3 | CID 216326 – structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem
Daratumumab is een experimentele monoklonale antistof die wordt ingezet tegen multipel myeloom. Daratumumab bindt aan CD38.[1] Daratumumab werd oorspronkelijk ontwikkeld door Genmab, maar wordt nu doorontwikkeld in samenwerking met Janssen Biotech, een dochteronderneming van Johnson & Johnson. De wereldwijde rechten op het medicament